Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control
Top-Line Phase 3 Data Demonstrate 86.0% Efficacy, which Met Primary Study Endpoint, and 98.7% Efficacy when Used as Directed
Q2 2019 New Drug Application (NDA) Resubmission Planned
Management to Host Conference Call at 8:30 a.m. EST
SAN DIEGO, Dec... Biopharmaceuticals Evofem Biosciences, Amphora, birth control
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news